Skip to main content
. 2018 Mar 17;8(3):e019214. doi: 10.1136/bmjopen-2017-019214

Figure 3.

Figure 3

Proportion of patients on pharmacological treatment at baseline and follow-up. ASA, acetylsalicylic acid; DPP-4, dipeptidyl peptidase 4; GLP, glucagon-like peptide; OAD, oral antidiabetic drug; RAS, renin–angiotensin system; SU, sulphonylurea.